Insider · CIK 0001612528

COATS LONNEL

Reports to the SEC for 4 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001612528

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-09	RLAYRelay Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+32.9K sh	—	—	32,947
2025-11-04	RLAYRelay Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+208K sh	—	—	207,931
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−136K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−42.2K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−11.8K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−4,500 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,300 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,300 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−4,570 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−4,875 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−3,188 sh	—	—	0
2025-07-17	Blueprint Medicines CorpD Disposition to Issuer	Director	DDisposition to Issuer	−6,144 sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.9K sh	—	—	0
2025-07-17	Blueprint Medicines CorpStock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.9K sh	—	—	0
2025-06-18	Blueprint Medicines CorpA Award	Director	AAward	+3,902 sh	$12812.00	+$50M	6,144
2025-06-05	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+42.2K sh	—	—	42,200
2024-11-21	Blueprint Medicines CorpS Sale	Director	SSale	−9,824 sh	$94.87	−$932K	2,242
2024-11-20	Blueprint Medicines CorpS Sale	Director	SSale	−213 sh	$94.99	−$20.2K	12,066
2024-11-20	Blueprint Medicines CorpS Sale	Director	SSale	−4,500 sh	$93.15	−$419K	17,566
2024-11-20	Blueprint Medicines CorpM Exercise/Conversion	Director	MExercise/Conversion	+1,312 sh	$76.24	+$100K	22,066
2024-11-20	Blueprint Medicines CorpM Exercise/Conversion	Director	MExercise/Conversion	+7,500 sh	$69.79	+$523K	20,754
2024-11-20	Blueprint Medicines CorpS Sale	Director	SSale	−5,287 sh	$94.24	−$498K	12,279
2024-11-20	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,312 sh	—	—	3,188
2024-11-20	Blueprint Medicines CorpStock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−7,500 sh	—	—	0
2024-06-26	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+136K sh	—	—	136,139
2024-06-12	Blueprint Medicines CorpA Award	Director	AAward	+2,242 sh	—	—	13,254
2024-06-12	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Director	AAward	+4,570 sh	—	—	4,570
2024-02-28	LXRXLEXICON PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−120K sh	—	—	240,767
2024-02-28	LXRXLEXICON PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+120K sh	—	—	1,159,439
2024-02-28	LXRXLEXICON PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−91.4K sh	—	—	91,363
2024-02-28	LXRXLEXICON PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−33.3K sh	—	—	0
2024-02-28	LXRXLEXICON PHARMACEUTICALS, INC.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−61.4K sh	$2.62	−$161K	1,098,068
2024-02-28	LXRXLEXICON PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+91.4K sh	—	—	1,039,056
2024-02-28	LXRXLEXICON PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+33.3K sh	—	—	947,692
2024-02-08	LXRXLEXICON PHARMACEUTICALS, INC. · Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+770K sh	—	—	770,420
2024-02-08	LXRXLEXICON PHARMACEUTICALS, INC. · Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+770K sh	—	—	770,420
2023-11-16	LXRXLEXICON PHARMACEUTICALS, INC.P Purchase	Director, Chief Executive Officer	PPurchase	+90K sh	$1.05	+$94.8K	914,359
2023-11-10	LXRXLEXICON PHARMACEUTICALS, INC.P Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$1.01	+$10.1K	824,359
2023-06-29	LXRXLEXICON PHARMACEUTICALS, INC.P Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$2.16	+$21.6K	814,359
2023-06-26	LXRXLEXICON PHARMACEUTICALS, INC.P Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$2.18	+$21.8K	804,359
2023-06-23	LXRXLEXICON PHARMACEUTICALS, INC.P Purchase	Director, Chief Executive Officer	PPurchase	+10K sh	$2.50	+$25K	794,359
2023-06-22	LXRXLEXICON PHARMACEUTICALS, INC.P Purchase	Director, Chief Executive Officer	PPurchase	+40K sh	$2.31	+$92.4K	784,359
2023-06-21	Blueprint Medicines CorpA Award	Director	AAward	+2,600 sh	—	—	11,012
2023-06-21	Blueprint Medicines CorpStock Option (Right to Buy)A Award	Director	AAward	—	—	—	—
2023-06-15	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+26.6K sh	—	—	26,642
2023-02-28	LXRXLEXICON PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+33.3K sh	—	—	703,967
2023-02-28	LXRXLEXICON PHARMACEUTICALS, INC.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+91.4K sh	—	—	795,330
2023-02-28	LXRXLEXICON PHARMACEUTICALS, INC.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−51K sh	$2.17	−$111K	744,359
2023-02-28	LXRXLEXICON PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−91.4K sh	—	—	182,727
2023-02-28	LXRXLEXICON PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−84.6K sh	—	—	0

Recent filings

Accepted (ET)
Jun 104
COATS LONNEL0001193125-26-265908
SEC(opens sec.gov)
Nov 64
COATS LONNEL0001193125-25-269790
SEC(opens sec.gov)
Jul 284
COATS LONNEL0000950170-25-099257
SEC(opens sec.gov)
Jul 214
COATS LONNEL0001104659-25-069392
SEC(opens sec.gov)
Jun 244
COATS LONNEL0001415889-25-018069
SEC(opens sec.gov)
Jun 64
COATS LONNEL0000950170-25-083233
SEC(opens sec.gov)
Nov 224
COATS LONNEL0001415889-24-027545
SEC(opens sec.gov)

Companies

Address

C/O RELAY THERAPEUTICS, INC. 60 HAMPSHIRE STREET

CAMBRIDGE, MA, 02139